<DOC>
	<DOCNO>NCT00448708</DOCNO>
	<brief_summary>This multi-center clinical study subject require arteriovenous graft upper extremity hemodialysis access . All subject provide inform consent undergo study procedure . The study consist multiple subject visit telephone contact 52 week study period . During study period subject must also maintain appropriate hemodialysis schedule . IDE Number : G060250</brief_summary>
	<brief_title>Safety Efficacy Angiotech Vascular Wrap Paclitaxel-Eluting Mesh Hemodialysis Vascular Access</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. ≥ 18 year age ; 2. female childbearing potential , provide evidence negative pregnancy test within 3 day prior graft placement ( Day 3 Day 0 ) ; 3. candidate new endtoside arteriovenous anastomosis graft place upper extremity ; 4. outflow vein great equal 3 mm diameter ; 5. able effectively communicate study personnel ; 6. consider physician available subsequent visit ; 7. willing comply aspect treatment evaluation schedule 52 week duration ; 8. allow representative sponsor , designate CRO , Institutional Review Board ( IRB ) , Ethics Committee , U.S. Food Drug Administration ( FDA ) review his/her relevant medical record ; 9. sign date IRBapproved write informed consent prior initiation study procedure , include screening procedure ; 10. must agree participate protocol 014VWAV07 , safety study run consecutively additional 4 year PostMarket Approval ( PMA ) , whichever longer ; 11. Lifespan® ePTFE Vascular Graft successfully implant . 1. pregnant , breastfeeding , female childbearing potential agree remain abstinent use contraceptive method study period . Nonchildbearing potential define either postmenopausal ( amenorrheic least 1 year ) surgically sterile . Surgically sterile define tubal ligation absence uterus and/or ovary ; 2. male childbearing potential , agree remain abstinent use contraception prevent father child course study . Nonchildbearing potential define vasectomy bilateral orchiectomy ; 3. central venous stenosis ipsilateral side document ; 4. hypercoagulable state document ; 5. life expectancy le one year ; 6. organ transplant expect within 6 month test control product ( study product ) placement ; 7. hypersensitivity component study product procedural material medication know ; 8. concurrently involve another investigational study ; 9. study product investigate others receive within 30 day prior randomization trial ; 10. study product study trial previously receive ; 11. uncontrolled hypertension systolic BP &gt; 200mmHg diastolic BP &gt; 115mmHg present screening ; 12. currently receive chemotherapy radiation therapy ; 13. placement new endtoend arteriovenous anastomosis graft require .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Hemodialysis Access</keyword>
</DOC>